X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs GLENMARK PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD GLENMARK PHARMA LUPIN LTD/
GLENMARK PHARMA
 
P/E (TTM) x 161.5 20.3 795.4% View Chart
P/BV x 3.0 3.6 82.7% View Chart
Dividend Yield % 0.8 0.3 251.0%  

Financials

 LUPIN LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
GLENMARK PHARMA
Mar-17
LUPIN LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,750993 176.2%   
Low Rs1,384729 189.7%   
Sales per share (Unadj.) Rs387.4325.5 119.0%  
Earnings per share (Unadj.) Rs56.639.3 144.1%  
Cash flow per share (Unadj.) Rs76.848.7 157.9%  
Dividends per share (Unadj.) Rs7.502.00 375.0%  
Dividend yield (eoy) %0.50.2 206.1%  
Book value per share (Unadj.) Rs298.9159.2 187.7%  
Shares outstanding (eoy) m451.58282.17 160.0%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x4.02.6 152.9%   
Avg P/E ratio x27.721.9 126.2%  
P/CF ratio (eoy) x20.417.7 115.2%  
Price / Book Value ratio x5.25.4 96.9%  
Dividend payout %13.25.1 260.2%   
Avg Mkt Cap Rs m707,513242,991 291.2%   
No. of employees `00016.813.0 129.5%   
Total wages/salary Rs m28,49516,408 173.7%   
Avg. sales/employee Rs Th10,418.37,083.9 147.1%   
Avg. wages/employee Rs Th1,697.01,265.4 134.1%   
Avg. net profit/employee Rs Th1,523.0855.1 178.1%   
INCOME DATA
Net Sales Rs m174,94391,857 190.5%  
Other income Rs m1,065374 285.1%   
Total revenues Rs m176,00892,230 190.8%   
Gross profit Rs m44,93120,367 220.6%  
Depreciation Rs m9,1222,644 345.1%   
Interest Rs m1,5252,373 64.3%   
Profit before tax Rs m35,34915,724 224.8%   
Minority Interest Rs m-720-   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m9,7853,827 255.7%   
Profit after tax Rs m25,57511,088 230.7%  
Gross profit margin %25.722.2 115.8%  
Effective tax rate %27.724.3 113.7%   
Net profit margin %14.612.1 121.1%  
BALANCE SHEET DATA
Current assets Rs m119,54268,746 173.9%   
Current liabilities Rs m61,20627,027 226.5%   
Net working cap to sales %33.345.4 73.4%  
Current ratio x2.02.5 76.8%  
Inventory Days Days7685 89.4%  
Debtors Days Days9096 94.1%  
Net fixed assets Rs m131,66024,132 545.6%   
Share capital Rs m903282 320.1%   
"Free" reserves Rs m134,07344,643 300.3%   
Net worth Rs m134,97644,925 300.4%   
Long term debt Rs m56,47845,363 124.5%   
Total assets Rs m266,073117,639 226.2%  
Interest coverage x24.27.6 317.0%   
Debt to equity ratio x0.41.0 41.4%  
Sales to assets ratio x0.70.8 84.2%   
Return on assets %10.211.4 89.0%  
Return on equity %18.924.7 76.8%  
Return on capital %19.319.1 100.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m81,88556,152 145.8%   
Fx outflow Rs m21,5068,084 266.0%   
Net fx Rs m60,37848,068 125.6%   
CASH FLOW
From Operations Rs m41,1486,574 625.9%  
From Investments Rs m-25,287-7,124 355.0%  
From Financial Activity Rs m4,3325,432 79.8%  
Net Cashflow Rs m20,1931,992 1,013.5%  

Share Holding

Indian Promoters % 46.6 48.3 96.5%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 6.9 163.8%  
FIIs % 31.9 34.4 92.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 10.5 96.2%  
Shareholders   98,259 56,727 173.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  UNICHEM LAB  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Jun 21, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS